SCHEMBL7555353

SCHEMBL7555353

COc1ccc(C2C(=O)N(C)C(=N)N[C@]2(C)c2cnc(-c3cccc(C#N)c3)s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 7/20 0.40
CYP3A4 P08684 7/20 0.40
CYP1A2 P05177 6/20 0.40
TSHR P16473 4/20 0.37
MAPK1 P28482 3/20 0.37
CASP1 P29466 3/20 0.37
HIF1A Q16665 2/20 0.37
ALDH1A1 P00352 4/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 2/20 0.36
HSD17B10 Q99714 1/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
BACE1 P56817 4/20 0.34
MCHR1 Q99705 2/20 0.33
LMNA P02545 1/20 0.33
CLK4 Q9HAZ1 2/20 0.33
CYP2D6 P10635 1/20 0.33
NPBWR1 P48145 1/20 0.33
TNF P01375 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205394 0.93 USP2 (0.41) USP2CYP3A4CYP1A2TSHRMAPK1
SCHEMBL7563145 0.91 USP2 (0.32) USP2CYP3A4CYP1A2
SCHEMBL7557111 0.91 TNF (0.34) USP2CYP3A4CYP1A2BACE1TNF
SCHEMBL13054903 0.85 BACE1 (0.45) CYP3A4CYP2C9BACE1CYP2D6
SCHEMBL7554813 0.85 BACE1 (0.45) CYP3A4CYP2C9BACE1CYP2D6
SCHEMBL12174242 0.84
SCHEMBL8205800 0.83 BACE1 (0.36) BACE1TNF
SCHEMBL13054897 0.81 BACE1 (0.36) USP2CYP3A4CYP1A2TSHRMAPK1
SCHEMBL7541955 0.81 BACE1 (0.36) USP2CYP3A4CYP1A2TSHRMAPK1
SCHEMBL12174278 0.79 MAPT (0.34) MAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829036-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 USP2 1767/4885CYP3A4 853/4885CYP1A2 2191/4885
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D USP2 3048/4885CYP3A4 871/4885CYP1A2 2524/4885
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D USP2 3048/4885CYP3A4 871/4885CYP1A2 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.